JP7200093B2 - がん治療用ｔｌｒ９アゴニストを用いた免疫調節 - Google Patents

がん治療用ｔｌｒ９アゴニストを用いた免疫調節 Download PDF

Info

Publication number
JP7200093B2
JP7200093B2 JP2019514720A JP2019514720A JP7200093B2 JP 7200093 B2 JP7200093 B2 JP 7200093B2 JP 2019514720 A JP2019514720 A JP 2019514720A JP 2019514720 A JP2019514720 A JP 2019514720A JP 7200093 B2 JP7200093 B2 JP 7200093B2
Authority
JP
Japan
Prior art keywords
imo
tumor
cancer
administered
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529415A (ja
JP2019529415A5 (enExample
Inventor
アグラワル，スディール
ワン，ダーチン
ジャン，ウェイン
Original Assignee
アイデラ・ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイデラ・ファーマシューティカルズ，インコーポレーテッド filed Critical アイデラ・ファーマシューティカルズ，インコーポレーテッド
Publication of JP2019529415A publication Critical patent/JP2019529415A/ja
Publication of JP2019529415A5 publication Critical patent/JP2019529415A5/ja
Priority to JP2021170043A priority Critical patent/JP2022009200A/ja
Application granted granted Critical
Publication of JP7200093B2 publication Critical patent/JP7200093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019514720A 2016-09-15 2017-09-15 がん治療用ｔｌｒ９アゴニストを用いた免疫調節 Active JP7200093B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021170043A JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662394845P 2016-09-15 2016-09-15
US62/394,845 2016-09-15
US201762486738P 2017-04-18 2017-04-18
US62/486,738 2017-04-18
PCT/US2017/051742 WO2018053242A1 (en) 2016-09-15 2017-09-15 Immune modulation with tlr9 agonists for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021170043A Division JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Publications (3)

Publication Number Publication Date
JP2019529415A JP2019529415A (ja) 2019-10-17
JP2019529415A5 JP2019529415A5 (enExample) 2020-11-05
JP7200093B2 true JP7200093B2 (ja) 2023-01-06

Family

ID=61620152

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019514720A Active JP7200093B2 (ja) 2016-09-15 2017-09-15 がん治療用ｔｌｒ９アゴニストを用いた免疫調節
JP2021170043A Pending JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021170043A Pending JP2022009200A (ja) 2016-09-15 2021-10-18 がん治療用ｔｌｒ９アゴニストを用いた免疫調節

Country Status (10)

Country Link
US (6) US10463686B2 (enExample)
EP (1) EP3512499A4 (enExample)
JP (2) JP7200093B2 (enExample)
KR (1) KR20190096936A (enExample)
CN (1) CN110114057A (enExample)
AU (1) AU2017325981A1 (enExample)
CA (1) CA3036978A1 (enExample)
IL (2) IL292658A (enExample)
MX (1) MX2019002925A (enExample)
WO (1) WO2018053242A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
CA3116733A1 (en) * 2018-10-18 2020-04-23 Idera Pharmaceuticals, Inc. Tlr9 modulators for treating cancer
JP2022508049A (ja) * 2018-11-01 2022-01-19 ファロン ファーマシューティカルズ オサケ ユキチュア 代替的に活性化されたマクロファージでのｃｌｅｖｅｒ－１発現のダウンレギュレーションに使用するためのｔｌｒ９アゴニスト
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
MX2022011155A (es) * 2020-03-09 2023-01-04 Dynavax Tech Corp Inmunización activa de refuerzo contra tétanos, difteria y tosferina.
DE112021004970T5 (de) * 2020-09-22 2023-07-06 Trisalus Life Sciences, Inc. Krebstherapie unter verwendung von toll-like-rezeptor-agonisten
CA3217279A1 (en) 2021-05-04 2022-11-10 Olga Ignatovich Anti-tigit antibodies and methods of use thereof
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017259T2 (de) 1999-08-13 2005-12-08 Hybridon, Inc., Cambridge Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
DK1992635T3 (da) * 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
JP4874801B2 (ja) 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
CN100482673C (zh) 2003-07-15 2009-04-29 艾德拉药物股份有限公司 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用
MXPA06000619A (es) 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
US7498425B2 (en) 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
BRPI0512110A (pt) 2004-06-15 2007-10-23 Idera Pharmaceutical Inc multìmeros de oligonucleotìdeos imunoestimulatórios
WO2007008463A2 (en) 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
ES2377884T3 (es) 2005-11-04 2012-04-02 Novartis Vaccines And Diagnostics S.R.L. Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1962909A4 (en) 2005-12-20 2012-04-18 Idera Pharmaceuticals Inc IMMUNOSTIMULATING ACTIVITY OF PALINDROMIC IMMUNOMODULATORY OLIGONUCLEOTIDES (IMO TM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS
US20080031887A1 (en) 2006-06-30 2008-02-07 Joseph Lustgarten Conjugates for inducing targeted immune responses and methods of making and using same
EP2079305A4 (en) 2006-12-12 2010-01-27 Idera Pharmaceuticals Inc SYNTHETIC AGONISTS OF TLR9
CA2693266C (en) 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
JP2012516352A (ja) 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
CA2788284A1 (en) 2010-02-09 2011-08-18 Georgia Health Sciences University Research Institute, Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
WO2013043647A1 (en) * 2011-09-19 2013-03-28 The Johns Hopkins University Cancer immunotherapy
WO2014047085A2 (en) 2012-09-20 2014-03-27 Rongfu Wang Prostate-specific tumor antigen and uses thereof
WO2015061752A1 (en) 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2016030863A1 (en) * 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
CA2975432A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
EP3302501B1 (en) 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
KR102779525B1 (ko) 2015-05-29 2025-03-12 다이나박스 테크놀로지 코퍼레이션 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｃａｎｃｅｒ Ｉｍｍｕｎｏｌ． Ｒｅｓ． （Ｊａｎ ２０１６） ｖｏｌ．４， Ｉｓｓｕｅ １ Ｓｕｐｐｌ．， Ａｂｓｔｒａｃｔ Ｂ１５３
Ｍｏｄｕｌａｔｉｏｎ ｏｆ Ｃｈｅｃｋｐｏｉｎｔ Ｅｘｐｒｅｓｓｉｏｎ ｉｎ Ｔｕｍｏｒ Ｍｉｃｒｏｅｎｖｉｒｏｎｍｅｎｔ ｂｙ Ｉｎｔｒａｔｕｍｏｒａｌ Ａｄｍｉｎｉｓｔｒａｔｉｏｎ ｏｆ ａ Ｎｏｖｅｌ ＴＬＲ９ Ａｇｏｎｉｓｔ： Ｒａｔｉｏｎａｌｅ ｆｏｒ Ｃｏｍｂｉｎａｔｉｏｎ Ｔｈｅｒａｐｙ， ＣＲＩ－ＣＩＭＴ－ＥＡＴＩ－ＡＡＣＲ Ｔｈｅ Ｉｎａｕｇｕｒａｌ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｃａｎｃｅｒ Ｉｍｍｕｎｏｔｈｅｒａｐｙ Ｃｏｎｆｅｒｅｎｃｅ， Ｎｅｗ Ｙｏｒｋ， ＮＹ， Ｓｅｐｔｅｍｂｅｒ １６－１９， ２０１５， ［ｒｅｔｒｉｅｖｅｄ ｏｎ ２０２０－１２－０３］， ＜ｈｔｔｐｓ：／／ｗｗｗ．ｉｄｅｒａｐｈａｒｍａ．ｃｏｍ／ｗｐ－ｃｏｎｔｅｎｔ／ｕｐｌｏａｄｓ／２０１５／０９／ｉｄｅｒａ＿ａａｃｒ＿２０１５＿ｃｈｅｃｋｐｏｉｎｔ＿ｆｉｎａｌ．ｐｄｆ＞
ＮＣＴ０２６４４９６７ Ａ Ｓｔｕｄｙ ｔｏ Ａｓｓｅｓｓ ｔｈｅ Ｓａｆｅｔｙａｎｄ Ｅｆｆｉｃａｃｙ ｏｆ Ｉｎｔｒａｔｕｍｏｒａｌ ＩＭＯ－２１２５ ｉｎ Ｃｏｍｂｉｎａｔｉｏｎ Ｗｉｔｈ Ｉｐｉｌｉｍｕｍａｂ ｏｒＰｅｍｂｒｏｌｉｚｕｍａｂ ｉｎ Ｐａｔｉｅｎｔｓ Ｗｉｔｈ Ｍｅｔａｓｔａｔｉｃ Ｍｅｌａｎｏｍａ， ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ， ［ｏｎｌｉｎｅ］，２０１６－０６－０２， ［ｒｅｔｒｉｅｖｅｄ ｏｎ ２０２０－１２－０３］， ＜ｈｔｔｐｓ：／／ｃｌｉｎｉｃａｌｔｒｉａｌｓ．ｇｏｖ／ｃｔ２／ｈｉｓｔｏｒｙ／ＮＣＴ０２６４４９６７？Ｖ＿４＝Ｖｉｅｗ＃ＳｔｕｄｙＰａｇｅＴｏｐ＞

Also Published As

Publication number Publication date
US11224611B2 (en) 2022-01-18
IL265370B (en) 2022-06-01
US20220088054A1 (en) 2022-03-24
CA3036978A1 (en) 2018-03-22
US20210052625A1 (en) 2021-02-25
US20200138848A1 (en) 2020-05-07
WO2018053242A1 (en) 2018-03-22
JP2022009200A (ja) 2022-01-14
US10463686B2 (en) 2019-11-05
US20180125877A1 (en) 2018-05-10
EP3512499A1 (en) 2019-07-24
AU2017325981A1 (en) 2019-04-11
US10772907B2 (en) 2020-09-15
JP2019529415A (ja) 2019-10-17
IL292658A (en) 2022-07-01
IL265370A (en) 2019-05-30
US10835550B2 (en) 2020-11-17
US20200054663A1 (en) 2020-02-20
CN110114057A (zh) 2019-08-09
MX2019002925A (es) 2019-09-05
KR20190096936A (ko) 2019-08-20
US20210038630A1 (en) 2021-02-11
EP3512499A4 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
US11224611B2 (en) Immune modulation with TLR9 agonists for cancer treatment
US20230374503A1 (en) Combination
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
JP2021529741A (ja) がん治療
WO2022166909A1 (en) Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug
KR20180015269A (ko) 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
WO2018075447A1 (en) Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
CN113677402A (zh) 治疗肿瘤的方法
US20190083556A1 (en) Analytical methods and arrays for use in the same
US20210340544A1 (en) Tlr9 modulators for treating cancer
EP4583888A1 (en) Modified t-cells for use in the treatment of bladder cancer
HK40058967A (en) Tlr9 modulators for treating cancer
HK1238287B (en) Combination
HK1238287A1 (en) Combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200915

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200915

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200928

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211018

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211112

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211217

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211221

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221017

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20221115

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20221208

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20221208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221221

R150 Certificate of patent or registration of utility model

Ref document number: 7200093

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150